[1]李怀东,李昕泽. 小干扰RNA研究概况[J]. 世界最新医学信息文摘,2019,19(35):116-117.
[2]陈忠斌,于乐成,王升启. RNA干扰作用(RNAi)研究进展[J]. 中国生物化学与分子生物学报,2002(5):525-528.
[3]SUBHAN M A,TORCHILIN V. siRNA based drug design,quality,delivery and clinical translation[J]. Nanomedicine:nanotechnology,biology and medicine,2020,29(1):102239.
[4]CORYDON I J,FABIAN-JESSING B K,JAKOBSEN T S,et al. 25 years of maturation:A systematic review of RNAi in the clinic[J]. Molecular therapy-nucleic acids,2023,33(3):469-482.
[5]DAR S A,THAKUR A,QURESHI A,et al. siRNAmod:A database of experimentally validated chemically modified siRNAs[J]. Scientific reports,2016,6(1):20031.
[6]SETTEN R L,ROSSI J J,HAN S. The current state and future directions of RNAi-based therapeutics[J]. Nature reviews drug discovery,2019,18(6):421-446.
[7]FRIEDRICH M,AIGNER A. Therapeutic siRNA:State-of-the-art and future perspectives[J]. BioDrugs,2022,36(5):549-571.
[8]张琼丹,陈朝霞,李芾瑶,等. siRNA纳米递送系统研究进展[J]. 生物化学与生物物理进展,2022,49(6):1018-1035.
[9]XU C,LI D,CAO Z,et al. Facile hydrophobization of siRNA with anticancer drug for non-cationic nanocarrier-mediated systemic delivery[J]. Nano letters,2019,19(4):2688-2693.
[10]CROOKE S T,BAKER B F,CROOKE R M,et al. Antisense technology:an overview and prospectus[J]. Nature reviews drug discovery,2021,20(6):427-453.
[11]FANG F,WANG S,SONG Y,et al. Continuous spatiotemporal therapy of a full-API nanodrug via multi-step tandem endogenous biosynthesis[J]. Nature communications,2023,14(1):1660.
[12]TAI W. Chemical modulation of siRNA lipophilicity for efficient delivery[J]. Journal of controlled release,2019,307(15):98-107.
[13]LEE J W,CHOI J,CHOI Y,et al. Molecularly engineered siRNA conjugates for tumor-targeted RNAi therapy[J]. Journal of controlled release,2022,351(18):713-726.
[14]李琛,司笑,李金波,等. 小干扰RNA药物的化学修饰及递送系统[J]. 化学学报,2023,81(9):1-18.
[15]SELVAM C,MUTISYA D,PRAKASH S,et al. Therapeutic potential of chemically modified siRNA:Recent trends[J]. Chemical biology & drug design,2017,90(5):665-678.
[16]MAGUREGUI A,ABE H. Developments in siRNA modification and ligand conjugated delivery to enhance RNA interference ability[J]. ChemBioChem,2020,21(13):1808-1815.
[17]JUAN M C,MEGAN K,VEERAJ S,et al. Albumin-binding RNAi conjugate for carrier free treatment of arthritis[J]. Biosystems engineering,2023,10(5):542971.
[18]LAURSEN M B,PAKULA M M,GAO S,et al. Utilization of unlocked nucleic acid(UNA)to enhance siRNA performance in vitro and in vivo[J]. Molecular biosystems,2010,6(5):862.
[19]FESLER A,HWANG G R,JU J. Development of novel 5-FU modified siRNA against BCL-2 with enhanced efficacy and vehicle-free cellular uptake[J]. Genes & diseases,2024,11(1):23-25.
[20]SOUTSCHEK J,AKINC A,BRAMLAGE B,et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs[J]. Nature,2004,432(7014):173-178.
[21]FERNANDEZ C,GIORGEES I,GOSS E,et al. Effective carrier-free gene-silencing activity of sphingosine-modified siRNAs[J]. Organic & biomolecular chemistry,2023,21(10):2107-2117.
[22]ZHENG Y,TAI W. Insight into the siRNA transmembrane delivery—from cholesterol conjugating to tagging[J]. WIREs nanomedicine and nanobiotechnology,2020,12(3):e1606.
[23]OSBORN M F,COLES A H,BISCANS A,et al. Hydrophobicity drives the systemic distribution of lipid-conjugated siRNAs via lipid transport pathways[J]. Nucleic acids research,2019,47(3):1070-1081.
[24]SUGO T,TERADA M,OIKAWA T,et al. Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles[J]. Journal of controlled release,2016,237(17):1-13.
[25]TAI W. Current aspects of siRNA bioconjugate for in vitro and in vivo delivery[J]. Molecules,2019,24(12):2211.
[26]YU Z,ZHANG X,PEI X,et al. Antibody-siRNA conjugates(ARCs)using multifunctional peptide as a tumor enzyme cleavable linker mediated effective intracellular delivery of siRNA[J]. International journal of pharmaceutics,2021,606(17):120940.
[27]WANG X,XIAO X,FENG Y,et al. A photoresponsive antibody-siRNA conjugate for activatable immunogene therapy of cancer[J]. Chemical science,2022,13(18):5345-5352.
[28]KLABENKOVA K,FOKINA A,STETSENKO D. Chemistry of peptide-oligonucleotide conjugates:A review[J]. Molecules,2021,26(17):5420.
[29]FU C,YU L,MIAO Y,et al. Peptide-drug conjugates(PDCs):a novel trend of research and development on targeted therapy,hype or hope?[J]. Acta pharmaceutica sinica B,2023,13(2):498-516.
[30]XIE X,LIN W,LI M,et al. Efficient siRNA delivery using novel cell-penetrating peptide-siRNA conjugate-loaded nanobubbles and ultrasound[J]. Ultrasound in medicine & biology,2016,42(6):1362-1374.
[31]YANG J,BAE H. Drug conjugates for targeting regulatory T cells in the tumor microenvironment:guided missiles for cancer treatment[J]. Experimental & molecular medicine,2023,55(9):1996-2004.
[32]SHARMA M,EL-SAYED N S,DO H,et al. Tumor-targeted delivery of siRNA using fatty acyl-CGKRK peptide conjugates[J]. Scientific reports,2017,7(1):6093.
[33]SIVAKUMAR P,KIM S,KANG H C,et al. Targeted siRNA delivery using aptamer-siRNA chimeras and aptamer-conjugated nanoparticles[J]. WIREs nanomedicine and nanobiotechnology,2019,11(3):e1543.
[34]ZHOU J,LAZAR D,LI H,et al. Receptor-targeted aptamer-siRNA conjugate-directed transcriptional regulation of HIV-1[J]. Theranostics,2018,8(6):1575-1590.
[35]JEONG E H,JEONG H,JANG B,et al. Aptamer-incorporated DNA holliday junction for the targeted delivery of siRNA[J]. Journal of industrial and engineering chemistry,2017,56(6):55-61.
[36]BEREZHNOY A,BRENNEMAN R,BAJGELMAN M,et al. Thermal stability of siRNA modulates aptamer-conjugated siRNA inhibition[J]. Molecular therapy-nucleic acids,2012,1(3):e51.
[37]CHEN S,LI D,DU X,et al. Carrier-free nanoassembly of doxorubicin prodrug and siRNA for combinationally inducing immunogenic cell death and reversing immunosuppression[J]. Nano today,2020,35(5):100924.
[38]SAW P E,YAO H,LIN C,et al. Stimuli-responsive polymer-prodrug hybrid nanoplatform for multistage siRNA delivery and combination cancer therapy[J]. Nano letters,2019,19(9):5967-5974.
[39]YANG Y,NING H,XIA T,et al. Electrostatic attractive self-delivery of siRNA and light-induced self-escape for synergistic gene therapy[J]. Advanced materials,2023,35(30):2301409.
[40]WITZIGMANN D,KULKARNI J A,LEUNG J,et al. Lipid nanoparticle technology for therapeutic gene regulation in the liver[J]. Advanced drug delivery reviews,2020,159(7):344-363.
[41]RANJBAR S,ZHONG X,MANAUTOU J,et al. A holistic analysis of the intrinsic and delivery-mediated toxicity of siRNA therapeutics[J]. Advanced drug delivery reviews,2023,201(10):115052.
[42]LEE J W,CHOI J,CHOI Y,et al. Molecularly engineered siRNA conjugates for tumor-targeted RNAi therapy[J]. Journal of controlled release,2022,351(21):713-726.
[43]ZHANG M M,BAHAL R,RASMUSSEN T P,et al. The growth of siRNA-based therapeutics:Updated clinical studies[J]. Biochemical pharmacology,2021,189(13):114432.